The cardiovascular effects of xanthines and selective PDE inhibitors: A risk–benefit analysis

Roberta Fusco, Rosanna Di Paola, Salvatore Cuzzocrea*, Maria Gabriella Matera, Clive Page

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Xanthines have been employed in the treatment of respiratory disorders since 1937, for the treatment of respiratory diseases such as COPD and asthma. However, xanthines, although effective, have a relatively narrow therapeutic window that has limited their wider use. Xanthines can also have important effects on the cardiovascular system. However, more recently, there has been the introduction of a number of selective phosphodiesterase 4 (PDE4) inhibitors for the treatment of inflammatory conditions, in particular roflumilast for the treatment of severe COPD. In addition, a number of PDE3 inhibitors have been approved for the treatment of a range of conditions, as PDE3 is widely expressed in cardiovascular tissues. The dual PDE3/4 inhibitor ensifentrine is also under development for the treatment of COPD. Here, we discuss the cardiovascular actions of xanthines and selective PDE inhibitors.

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalERS Monograph
Volume2020
Issue number9781849841191
DOIs
Publication statusPublished - 2020

Fingerprint

Dive into the research topics of 'The cardiovascular effects of xanthines and selective PDE inhibitors: A risk–benefit analysis'. Together they form a unique fingerprint.

Cite this